Glial pathology precedes symptoms of Parkinson's disease and multiple other neurodegenerative diseases. Prolonged impairment of astrocytic functions could increase the vulnerability of dopaminergic neurons in the substantia nigra (SN), accelerate their degeneration and affect ability to compensate for partial degeneration at the presymptomatic stages of the disease. The aim of this study was to investigate the astrocyte depletion in the SN, its impact on the dopaminergic system functioning and multiple markers of energy metabolism during the early stages of neurodegeneration and compensation. We induced death of 30% of astrocytes by chronic infusion of fluorocitrate (FC) into the SN, simultaneously activating microglia response but sparing the dopaminergic neurons. The FC effect was reversible after toxin withdrawal. Dopaminergic neurons were killed by 6-hydroxydopamine causing transient locomotor disability, reversed with time showing compensatory potential. Death of astrocytes diminished the capability of the dopaminergic system to compensate for the degeneration of neurons and caused a local energy deprivation by decreasing lactate and glycogen amount. Studied markers suggest a shift in the usage of energy substrates, via increased glycogenolysis and glycolysis markers, ketone bodies availability and fatty acid transport in remaining cells. Peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC-1alpha) and AMPactivated protein kinase (AMPK), the energy sensors, showed different regulation between the cell-types. Increased neuronal expression of carnitine palmitoyltransferase 1c could play a role in the adaptation to metabolic stress in response to glia dysfunction. Astrocyte energetic support is one of the essential factors for neuronal compensatory mechanisms of dopaminergic system and might have a leading role in the presymptomatic Parkinson's disease stages. Keywords: brain fatty acid metabolism, CPT1c, glycogen, ketone bodies, neurodegeneration, PGC-1a. Parkinson's disease (PD) is a slowly progressing neurodegenerative disorder that affects mostly the dopaminergic neurons in the substantia nigra (SN). The first motor symptoms show in older age, after at least 70% of the nigral neurons have been lost and dopamine (DA) level in its output structure -striatum (STR) decreased by 80% (Hornykiewicz 1998 Abbreviations used: AMPK, AMP-activated protein kinase, catalytic subunit alpha; b-HB, ß-hydroxybutyrate; CPT1a, glial carnitine palmitoyltransferase 1a; CPT1c, neuronal carnitine palmitoyltransferase 1c; GS, glutamine synthetase; mACO, mitochondrial aconitase; PDK2, pyruvate dehydrogenase kinase 2; PGC-1a, peroxisome proliferatoractivated receptor-gamma coactivator 1a; PKM2, pyruvate kinase M2.
Neurons are functionally linked with astrocytes Pellerin and Magistretti 1994 ) that act as sensors and adjust their energy metabolism to meet neuronal needs (Baltan 2015; Jha et al. 2016a) . Astrocytes are uniquely equipped to maintain energy homeostasis in the neural tissue (Dienel and Cruz 2006; Baltan 2015) (Fig. 1 ) and are strategically located at the neurovascular units for uptake of glucose (Mathiisen et al. 2010) . Astrocytes are the only cells in the brain having energy reserves in form of glycogen (Baltan 2015) . They are constitutively glycolytic, as compared to neurons that mainly use oxidative phosphorylation (OxPhos) for energy production (Bolanos 2016) . Astrocytes can supply different energy substrates to maintain neuronal activation, for example lactate or ketone bodies (Guzm an and Bl azquez 2001) . Astrocytes can perform gluconeogenesis (Yip et al. 2016) and are enriched in transcriptomes of genes encoding for enzymes involved in fatty acid oxidation (Eraso-Pichot et al. 2018 ).
Parkinson's disease (PD) is a slowly progressing neurodegenerative disorder that affects mostly the dopaminergic neurons in the substantia nigra (SN). The first motor symptoms show in older age, after at least 70% of the nigral neurons have been lost and dopamine (DA) level in its output structure -striatum (STR) decreased by 80% (Hornykiewicz 1998) . It indicates the existence of early, deficit masking compensatory mechanisms in presymptomatic PD. The dopaminergic neurons possess particularly high metabolic rate (Liang et al. 2007) . Functional and anatomical compensation for degeneration at early PD stages additionally puts higher energetic demands on remaining dopaminergic neurons. Some studies described the SN as particularly poor in astrocytes, compared to the other brain regions (Kim et al. 2000; Emsley and Macklis 2006) and containing a particular subtype of astrocytes (Oberheim et al. 2012; Kuter et al. 2017) . It indicates vulnerability of SN neurons. Dysregulation of energy-sensing and signaling pathways (Zheng et al. 2010; Elstner et al. 2011 ) and use of alternative carbon sources for energy production was described in PD patient brains (Dienel and Cruz 2006) . Defects of mitochondrial electron transport, especially complex I (Schapira et al. 1990 ), downregulation of OxPhos, pyruvate metabolism and tricarboxylic acid cycle (TCA) enzymes genes were shown in PD (Zheng et al. 2010) . Changes in the energy substrate levels in patient CSF indicate affected glucose metabolism ( € Ohman and Forsgren 2015) . Many of those processes were described as the early disease events already at the preclinical stages of PD.
Importantly, the pathologic changes in PD are observed not only in neuronal but also in glial cells. Along with Lewy bodies in neurons, activated astrocytes with a-synuclein inclusions were found in post mortem PD brains, at the early disease stages and their number increased with its progression (Wakabayashi et al. 2000; Braak et al. 2007 ). In addition, several of the proteins responsible for autosomal recessive forms of hereditary PD (Parkin, PINK-1, DJ-1) are mainly concentrated in astrocytes (Halliday and Stevens 2011) . The levels of protective astrocyte-derived neurotrophins decrease in advanced PD. It implies decreased protection from astrocytes with progression of PD pathology.
Most previous studies focused on acute glia disturbances (Paulsen et al. 1987 (Paulsen et al. , 1988 Hassel et al. 1992 Hassel et al. , 1994 Fonnum et al. 1997; Rodriguez Diaz et al. 2005; Hirose et al. 2007; Canals et al. 2008; Zielke et al. 2009 ). The studies on genetically induced models depleting astrocytes in long-term did not analyze SN so far (Cui et al. 2001; Nishiyama et al. 2002; Lee et al. 2014; Schreiner et al. 2015) . There were no studies localized to the SN, taking into the account the neuro-glia interaction, especially focused on the energy metabolism. No studies so far analyzed the compensatory potential of neurons in this aspect.
We hypothesize that prolonged impairment of the supportive role of astrocytes at early disease stage could increase the vulnerability of dopaminergic neurons. In particular disruption in energetic coupling between neuronal and astroglial cells could be the reason for a loss of compensation ability as suggested by Elstner et al. (2011) . The aim of this study was to investigate the changes in energy metabolism markers induced by the death of 30% of astrocytes in the SN. We wanted to find out how the prolonged in vivo astrocyte loss would impact the energy metabolism of the SN at the early stages of neuron degeneration and the compensation of animal locomotor dysfunction, corresponding to PD.
Our previous research (Kuter et al. 2017) documented that prolonged infusion of astrocytic toxin fluorocitrate (FC) into the SN caused death of approx. 30% of astrocytes (decreased S100+ cell density and expression of ALDH1L1), activation of remaining alive astrocytes (increased Glial Fibrillary Acidic Protein (GFAP) expression, changes in morphology) and concomitant activation of microglia, while sparing neurons. In the current study we further show that the astrocyte death induced also a local energy deprivation. It decreased lactate and glycogen amounts. Markers of enhanced glycogenolysis and glycolysis, increased ketone body concentration and fatty acid transport suggest a shift in the availability, therefore probably also usage of energy substrates in remaining glial cells. Observed changes were related to the microglia activation and influenced neuronal functioning. On the other hand, selective degeneration of approx. 50% of dopaminergic neurons in SN caused by 6-hydroxydopamine (6-OHDA) elicited temporal locomotor dysfunction compensated with time, but did not induce major metabolic changes in the studied parameters in the remaining tissue, corresponding with the presymptomatic stage of PD. Importantly, death of astrocytes diminished the capability of the dopaminergic system to compensate for the neuronal degeneration. This study proves that the astrocyte-neuron metabolic coupling is essential for the compensatory potential of the nigrostriatal system.
Materials and methods

Animals and brain operations
Three months old male Wistar HAN rats (Charles Rivers, Sulzfeld, Germany, RGD_13508588) were kept under 12 h dark/light cycle, with free access to food and water. The experiments were carried out in compliance with the Animal Experiments Bill of January 21, 2005 and according to the NIH Guide for the Care and Use of Laboratory Animals. The study received approval from the Local Ethics Committee (947/2012; 882/2012) . All efforts were made to minimize the number of animals and their suffering, such as providing pain medication to the animals and by various other methods, as described throughout the methods section. Stereotaxic brain operations were performed as described in Kuter et al. (2017) under ketamine and xylasine anesthesia (Biowet, Puławy, Poland) with desipramine (Sigma-Aldrich, Munich, Germany) to protect the noradrenergic terminals. To induce degeneration of dopaminergic neurons the animals were stereotaxically, bilaterally injected with 6-OHDA HBr (3 lg base/3 lL per side; SigmaAldrich) into the passing fibers of the medial forebrain bundle (MFB), at coordinates: AP: 1.4 mm, L: AE1.6 mm, V: 8.7 mm from bregma (Paxinos and Watson 2007) . Control -sham operated rats received solvent. The same animals had cannulas bilaterally, permanently implanted in the SN pars compacta (coordinates: AP: 4.9 mm, L: AE1.8 mm, V: 8.3 mm from bregma (Paxinos and Watson 2007) ) and connected to osmotic minipumps (1007D, ALZET; CharlesRivers), administering fluorocitrate (FC, 2 nmol/day; SigmaAldrich) for 7 days, to induce astrocyte dysfunction. On the 7th day after operation the rats were anesthetized again and minipumps were explanted. Control animals had cannulas implanted with sealed catheters. FC was prepared according to (Paulsen et al. 1987) . Rats received an antibiotic (100 lL/100 g, ip; Lincospectin, Pharmacia, Belgium) on the day of operation and 24 h afterwards.
The tissue samples were excised from the brain and blood collected immediately after decapitation. STR contained the whole structure and SN contained both part compacta and reticulate (AP: +2.52 till À2.52 mm from bregma; AP: À4.44 till À6.6 mm from bregma, respectively (Paxinos and Watson 2007) ).
Behavioral analysis
Locomotor activity of rats (path length, locomotion and resting times) and rearings (total, free and supported, number, duration) were measured exactly as published before (Kuter et al. 2016a (Kuter et al. , 2017 at 3, 5, 26 days after operation, using computerized actimeters (ACTI-FRAME-SYSTEM; GERB Elektronik GmbH, Berlin; Germany) during the light (6 h) and dark phase (12 h) of the day. Each analysis session included animals from all treatment groups, from the same post-operation day. If the same animal was tested twice, the observations were at least 3 weeks apart. The results from path length at given time-points were published as a part of time-line studies (Kuter et al. 2017) , calculated as % of control.
Western blot
Frozen tissue samples were lysed by sonication in radioimmunoprecipitation assay buffer (RIPA) buffer (50 mM Tris; 150 mM NaCl; 1% NP-40; 0.1% sodium dodecyl sulfate; 0.5% sodium deoxycholate; protease and phosphatase inhibitors, pH 7.4). Protein concentration in supernatants was determined using Pierce TM BCA Protein Assay Kit (Thermo Scientific, Waltham, Massachusetts, USA). Samples were mixed with loading buffer, heat denaturized and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Transfer to polyvinylidene difluoride (PVDF) membranes (Roche Diagnostics, Mannheim, Germany) was performed with semi-dry, discontinuous buffer system in Trans-Blot â Turbo TM (Bio-Rad Laboratories, Hercules, CA, USA). Blots were probed with primary antibodies against: tyrosine hydroxylase (TH) (Millipore Corporation, Bedford, MA, USA, MAB5280, RRID:AB_2201526), pyruvate dehydrogenase kinase 2 (PDK2, ab68164, RRID:AB_11156499), glutamine synthetase (GS, ab176562), mitochondrial aconitase (mACO, ab129105), carnitine palmitoyltransferase 1a (CPT1a, ab128568, RRID:AB_11141632) (all from Abcam, Milton, UK), AMP-activated protein kinase catalytic subunit a (AMPK, cat.no 5831), phosphorylated AMPK (pAMPK, cat.no 2531) (all from Cell Signaling Technology, Beverly, MA, USA), carnitine palmitoyltransferase 1c (CPT1c, sc-514555), peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC-1a, sc-517260), pyruvate kinase M2 (PKM2, sc-365684), b-actin (sc-47778) (all from Santa Cruz Biotechnology, Dallas, Texas, USA). Secondary anti-rabbit (Cell Signalling Technology) or anti-mouse (Santa Cruz Biotechnology) antibodies conjugated with horseradish peroxidase were used. Detection was done using chemiluminescence solution (0.1 M Tris; 5.3 mM H 2 O 2 ; 1.25 mM luminol; 2.0 M 4-iodophenylboronic acid) (Haan and Behrmann 2007) . After immunodetection membranes were stained with Coomassie blue and total protein staining in a lane was used as a loading control for each sample (Welinder and Ekblad 2011) . Analysis was performed at least in triplicate for each animal, with n = 5-7 animals per group.
Quantitative assays for metabolites
Tissue samples were homogenized in 0.1 M perchloric acid and pH of supernatants was adjusted with potassium hydroxide. The plasma was prepared by centrifugation. The assays for lactate and ß-hydroxybutyrate (b-HB) were performed on tissue homogenates using fluorescence PicoProbe kits according to the manufacturer protocols (K638-100 and K651-100; BioVision, Milpitas, California, USA). Glucose assay on plasma samples was performed according to the manufacturer protocol (BIOLABO, Maizy, France). For signal detection on 96-well plates, a Tecan 200 Infinite spectrophotometer (Tecan Group, Ltd., M€ annedorf, Switzerland) was used. Standard curves were prepared fresh on each wellplate separately. The data are presented as the mean values AE SEM from n = 5 to 7 animals per group for tissue homogenates and n = 8-9 for plasma samples.
Mitochondria isolation and aconitase activity assay
The assay was performed on crude mitochondrial tissue fractions isolated as published before (Kuter et al. 2016a,b) , according to kit K716 and manufacturer protocol (BioVision). Protein amounts in samples were determined using the Bradfordt test. Absorbance was measured at 450 nm using Tecan Infinite M1000 spectrophotometer (Tecan Group, Ltd.). Standard curves were prepared fresh on each wellplate. The data are presented as the mean values AE SEM from n = 4 to 7 animals per group.
Glycogen detection in tissue sections
Brain hemisphere, frozen in n-heptane on dry ice, was sectioned on a cryostat into 10 lm sections. Sections were air dried and incubated in 0.5% periodic acid. After washing in water, slides were incubated in Schiff reagent, washed again, dehydrated and cover-slipped. Control sections were preincubated with 0.2% amylase at 37°C for 30 min. Control staining was also performed with saturated solution of dimedone at 60°C for 10 min. The intensity of glycogen staining was estimated on high precision scans of tissue sections (Scanner Epson Perfection V750 Pro; Seiko Epson Corporation, Nagano, Japan) using Multi Gauge software (Fujifilm Holdings Corporation, Tokyo, Japan). Regions of interest were outlined and mean quant level per area (QL/pixel 2 ) was quantified from 2 to 3 sections per animal, 5-8 animals per group.
Statistical analysis
Results are presented as the mean AE SEM. The statistical analysis of the results was performed using STATISTICA 10.0 software (StatSoft Inc., Tulsa, OK, USA). p ≤ 0.05 was considered as statistically significant and 0.1 ≥ p > 0.05 were considered as trends. D'Agostino & Pearson normality test was performed using GraphPadPrism 7.04 (GraphPad Software Inc., San Diego, CA, USA). Analyses were done by two-way factorial ANOVA with Fisher least significant difference (LSD) post hoc test or one-way ANOVA with LSD post hoc test and t-test for comparison of groups in time. For motor behavior analysis repeated measures test was used. Grubbs test was used to identify outliers.
The study was not pre-registered. No blinding methods were employed in this study. No statistical sample size calculation was performed to predetermine the sample size. This experiment is a continuation of previous behavioral studies in the same models (Kuter et al. 2011 (Kuter et al. , 2016a (Kuter et al. , 2017 Berghauzen-Maciejewska et al. 2014 ) and we assessed the necessary minimum group size based on the sample size used in previous studies. Six animals were arbitrarily picked from the cohort by chance, each day and allocated to different experimental groups. No randomization procedures were employed in the allocation of animals to experimental groups. For behavioral analysis animals from each of experimental group, operated on the same day, were tested simultaneously. The automated locomotion cages were each day hosting animal from another experimental group. Tissue collection was kept in the same order of animals as set for operation, involving different time-points after operation groups. For biochemical studies and western blot all samples were tested at the same time with no randomization.
Results
Prolonged dysfunction of astrocytes blocks behavioral compensation of locomotor deficits
Behavioral analysis was performed to document the motor deficit induced by an early phase of dopaminergic neuron degeneration and its functional compensation with time ( Fig. 2a and Data S1). Motor disability was observed in almost all analyzed parameters in animals treated with 6-OHDA, 3 and 5 days post-lesioning (p ≤ 0.0001 for 3 days, p = 0.0112 for 5 days, path length). Most deficits were compensated and disappeared after 26 days (p = 0.25). Chronic treatment with FC caused a small and short-lasting behavioral deficit (only at 3 day time-point, p = 0.0016) and this effect was also reversed. On the other hand, combined treatment, causing both astrocyte and DA-neuron degeneration (Kuter et al. 2017) showed behavioral dysfunction during the whole analysis period and was never compensated (p ≤ 0.0001 for 3 days, p = 0.0006 for 5 days, p = 0.0027 for 26 days). Degeneration of dopaminergic neurons and astrocytes in the SN Injection of 6-OHDA into the MFB induced retrograde degeneration of dopaminergic neurons in the SN (Fig. 2b) . Decreased expression of neuronal marker protein, TH was detected already after 7 days from toxin injection and was not enhanced with time (p ≤ 0.0001 for both time-points).
The results from the animal groups receiving both 6-OHDA and FC were not different from 6-OHDA alone groups (p = 0.2975 for 7 days, p = 0.2485 for 4 weeks vs. LS).
From our previous studies we know that neuronal degeneration in this model is progressive but the decrease in TH expression and loss of dopaminergic phenotype precedes the actual death of neurons (Kuter et al. 2016a (Kuter et al. , 2017 . No significant changes in TH protein levels were detected after chronic FC infusion alone, although we observed a nonsignificant decrease, corresponding with our previous observation that FC did not kill dopaminergic neurons in this model but temporarily stressed them (Kuter et al. 2017) . The astrocytic marker protein GS showed a strong decrease after 7 days of FC infusion ( Fig. 2c ) with and without 6-OHDA treatment (p ≤ 0.0001 for both groups). Three weeks after FC discontinuation (4 weeks post operation) GS expression was restored, correlating with astrocyte replenishment (SF p = 0.6493 and LF p = 0.4529). This result further proves astrocyte death induced by FC, followed by replenishment of astrocytic pool with time, corresponding with data shown previously (Kuter et al. 2017) .
Lactate amount in the SN reflects astrocyte dysfunction Lactate is an interstitial energy substrate considered to be produced in astrocytes and shuttled to neurons to support their energy requirements . We analyzed its concentration in blood and homogenates from the brain dopaminergic structures, the SN and STR (Fig. 3) . While in plasma lactate levels were changed only in the group receiving both FC and 6-OHDA (non-significant decrease after 7 days and increase after 4 weeks p = 0.0285), in the SN its concentration decreased significantly after 7 days of FC treatment (by 9.8%, p = 0.0234 after FC alone, and by 24.4%, p ≤ 0.0001 after FC + 6-OHDA), corresponding with astrocyte degeneration. After 4 weeks and FC withdrawal, when glial cells replenished their pool and stayed activated, also lactate level increased (in FC alone groups, p = 0.002) or returned to control levels (FC and 6-OHDA group, p = 0.964). A tendency to decrease was also observed 7 days after 6-OHDA alone injection (p = 0.0515). On the other hand, no significant changes were observed in the STR, suggesting that the effect was related to the local glia functioning.
Plasma glucose level decrease after FC treatment
Glucose is the main energy substrate for the brain. We measured its levels in rats' plasma at two time-points after brain operation (Fig. 3) . After 7 days the effect of FC infusion was significant and it decreased plasma glucose concentration (SS = 8.27 AE 0.19; SF = 7.44 AE 0.19, p = 0.004; LF = 7.52 AE 0.23 nmol/lL plasma, p = 0.0092). On the other hand, after 4 weeks there were no changes after FC observed anymore but the effect of dopaminergic neuron degeneration after 6-OHDA injection was visible, also as decreased plasma glucose levels (SS = 8.28 AE 0.14; LS = 7.66 AE 0.07, p = 0.0296; LF = 7.55 AE 0.23 nmol/lL plasma, p = 0.0072).
Availiability of alternative energy sources Ketone bodies are an alternative energy substrate to the glucose. There was no change in the plasma b-HB level generated in the liver, meaning that physical condition of animals was normal (Fig. 3) (Fig. 3) . In the SN, a tendency towards increased b-HB levels still remained in all groups, even 4 weeks after operation.
Glycogen is a form of carbohydrate energy reserve in the brain and is produced and stored only in glial cells. Its expression in the SN correlated with the decreased density of astrocytes. Decreased glycogen amount was detected after 7 days (SS = 61.2 AE 1.19; SF = 30.2 AE 1.1, p ≤ 0.0001; LF = 31.79 AE 1.17 QL/pixel 2 , p ≤ 0.0001) and although slightly recovered it was still reduced after 4 weeks (SS = 65.97 AE 1.39; SF = 48.99 AE 1.69, p ≤ 0.0001; LF = 46.2 AE 1.85 QL/pixel 2 , p ≤ 0.0001) (Fig. 3) . In the STR only a small increase in glycogen expression was found after FC and 6-OHDA at 7 days (p = 0.0125).
The only cells in the brain able to use the fatty acids as energy substrates are astrocytes and they express CPT1a. CPT1c expressed in neurons is considered to be a sensor of lipid metabolism (Casals et al. 2016) .
Astrocytic CPT1a expression in SN was increased after FC alone and with 6-OHDA (p ≤ 0.006 and p ≤ 0.046, respectively) after 7 days and this effect diminished after 4 weeks (Fig. 4d) . The prolonged infusion of FC even stronger increased CPT1c neuronal expression in the SN (p ≤ 0.0001 for both SF and LF) and this effect was still visible after the toxin withdrawal (p = 0.0272 for SF) (Fig. 4c) . Despite 6-OHDA lesioning of the dopaminergic system and loss of 50% of neurons the level of CPT1c protein did not decrease.
Markers of glycolysis and TCA cycle
We analyzed expression of marker proteins at different steps of cellular energy production, from glycolysis to the TCA cycle.
PKM2 is a kinase that regulates the final, rate-limiting step of glycolysis by catalyzing the production of pyruvate and ATP (Yang and Lu 2015) . There were no changes observed in this protein expression either due to the FC or 6-OHDA treatment (Fig. 4a) .
The mitochondrial multienzyme pyruvate dehydrogenase (PDH) irreversibly converts pyruvate into acetyl-CoA, which is the primary fuel of the TCA cycle (Jha et al. 2016a) . PDH connects glycolysis to the oxidative metabolism. PDK2 kinase downregulates PDH activity by phosphorylation. PDK2 expression in the SN was strongly decreased after 7 days of FC infusion (p = 0.0001 and p = 0.002 for SF and LF). This effect was still observed after 4 weeks, although to a lesser extent (p = 0.0215 and p = 0.0376 for SF and LF) (Fig. 4b) . 6-OHDA lesioning had no effect on PDK2 protein amount.
Aconitase is one of the main enzymes in the TCA cycle. The prolonged, stable infusion of a small dose of FC into the SN induced local, very strong increase in mACO enzymatic activity after 7 days (SS = 0.0149 AE 0.0019; SF = 0.0636 AE 0.0078, p ≤ 0.0001; LF = 0.0481 AE 0.0043 nmol isocitrate/lg protein, p = 0.0004) (Fig. 5a ). After 4 weeks this effect diminished, although mACO activity still showed tendencies to be higher than in control samples. A tendency to increase mACO enzyme activity was also observed after 6-OHDA lesion alone. In the STR, a slight increase was detected only in the group treated with FC and 6-OHDA 7 days post operation (p = 0.0035) (Fig. 5b) . No significant changes in its protein amount in the SN were presented by western blot analysis (data not shown).
PGC-1a and AMPK expression
The transcription cofactor, responsible for controlling the oxidative metabolism and mitochondria biogenesis, PGC-1a showed highly increased protein expression in the SN after 7 days of FC infusion (p ≤ 0.0001 for SF and LF) (Fig. 6a) . After 4 weeks and withdrawal of the astrocytic toxin, this effect was diminished, yet still detectable (p = 0.0142 for SF). Death of dopaminergic neurons, caused by 6-OHDA injection into the MFB, did not influence PGC-1a amount. The phosphorylation of AMPK protein indicates its activity status which regulates the overall cellular energy metabolism. Surprisingly, both after FC alone and 6-OHDA alone treatments we observed tendencies to decrease the ratio of phosphorylated to total AMPK protein (p = 0.0852, p = 0.0588 respectively) (Fig. 6b) , instead of an increase. Additionally, after astrocyte recovery in the SN, at 4 week time-point, a slightly increased AMPK activity was detected in the combined FC + 6-OHDA treatment group (p = 0.0099).
Discussion
The prolonged dysfunction of astrocytes in an animal model Recently, we generated an animal model of selective, prolonged astrocyte dysfunction and death in the SN by 7-day constant infusion of a small dose of FC (Kuter et al. 2017) . Astrocytes replenished their pool after further 3 weeks of toxin withdrawal. Importantly, infusion of such a small FC dose did not kill neurons, although temporarily stressed them, what was reflected in an animal locomotor behavior after 3 days. In this study we focused on consequences of local astrocyte death on energy metabolism in the SN. Reduced GS, glycogen and lactate amounts are the direct indicators of the reduced number of astrocytic cells. The other markers described below are markers of energy metabolism of cells that remained in the tissue.
Energy substrates and reserves
The brain preferably uses glucose as an energy substrate (Achanta and Rae 2017) . Plasma glucose level can be an indirect marker of brain energy needs. Astrocytic end-feet cover 99.7% of the capillary, controlling glucose flux (Mathiisen et al. 2010) . We observed the decreased glucose level in rat plasma after astrocyte death (7 days) and in animals with dopaminergic system lesion after 4 weeks. It could indicate the increased brain glucose uptake and increased energy requirements. In agreement with our conclusion, Hirose et al. (2007) showed that injection of FC into the STR caused a significant increase in [18F]fluorodeoxyglucose uptake. Most tissues have additional energy sources in the form of fatty acids, but not the brain. Instead, glycogen and ketone bodies, such as b-HB, are an emergency fuel (Achanta and Rae 2017) . b-HB is produced mostly in the liver mitochondria from fatty acids or amino acids (Yudkoff et al. 1997) broken into acetyl-CoA. Importantly, b-HB is also synthesized in astrocytes, which are capable of oxidizing fatty acids in the brain (Eraso-Pichot et al. 2018). In our study, degeneration of portion of astrocytes induced an increase in the b-HB levels both in the SN and STR. Importantly; this effect was not coming from the liver, because the plasma levels of b-HB were unchanged. We documented before that remaining in the tissue astrocytes, surrounding the degeneration site, were activated (Kuter et al. 2017 ) and they were the source of ketone bodies. After replenishment of the astrocyte pool b-HB levels were mostly normalized. The increased b-HB level in both SN and STR is an interesting observation, since most of the changes in the analyzed energy parameters were observed locally in the SN (lactate, glycogen, mACO). The increase in b-HB concentration in the STR was smaller than in the SN. This could reflect the response of the dopaminergic terminals to the decreased glucose availability in plasma or/and adaptation of the STR astrocytes to support neurons in the SN stressed by FC infusion (as documented previously (Kuter et al. 2018) ).
Glycogen is the only energy reserve storage form in the brain (Obel et al. 2012; Jakobsen et al. 2017 ) located exclusively in the astrocytes (Hertz and Chen 2017) . Neurons rely on the energy sources from astrocytes and glycogenolysis was proven to be essential for neuronal functioning, for example during learning and memory consolidation (Dienel and Cruz 2006; Hertz and Chen 2017) . We show decreased glycogen amount in the SN, where astrocytes were damaged. It could result either from reduced number of astrocytes and diminished production of glycogen (7 days) or from the increased demand for energy supply from additional stores to support neuronal activity (4 weeks). Interestingly, even though the number of astrocytes was replenished after 4 weeks (Kuter et al. 2017 ) the amount of glycogen was still significantly decreased at that time, similarly to the most of other influenced parameters (lactate, b-HB, mACO activity, PDK2 and PGC-1a).
Furthermore, astrocytes actively regulate their glycogen stores with respect to the ambient glucose levels. In our results the decreased plasma glucose correlated with the decreased glycogen in the SN but not in the STR, which might suggest that the observed changes were not only due to the amount of available glucose but more importantly reflected local cellular activity.
It was described earlier that reduction in glycogen content was associated with an increase in neurotransmitter glutamate, the synthesis of which in the brain requires glycogenolysis (Hertz and Chen 2017) . This is important because glutamineprecursor of glutamate and GABA must be synthesized within the astrocytes. Therefore, disruption of astrocyte energy metabolism and glycogen stores influences neurotransmission. In the SN pars compacta most of neurons are dopaminergic but 29% are GABAergic (Nair-Roberts et al. 2008) . Hence, astrocyte death could impact their function, what was reflected in the animal locomotor behavior.
Interestingly, breakdown of glycogen during increased neuronal activity leads to a release of lactate rather than glucose from astrocytes via formation of pyruvate (Wiesinger et al. 1997; Baltan 2015; Hertz and Chen 2017) . It was reported that lactate shuttled from astrocytes to neurons fully supports neuronal function in the absence of glucose and becomes a preferred energy metabolite when axons discharge at high frequency (Schurr and Payne 2007; Jha et al. 2012; Bouzier-Sore and Pellerin 2013; Riske et al. 2017) but it fails to benefit axon function during an ischemic episode in white matter when astrocytes are affected (Baltan 2015) . It is in agreement with our observation. Also, other studies showed that FC decreased the lactate and glucose consumption and production (Hassel et al. 1994 (Hassel et al. , 1995 Rist et al. 1996; Zielke et al. 2007) . The decrease in lactate, only in the SN but not in the STR or blood, presented here, further proves selectivity of the FC effect.
Therefore, after a local destruction of astrocytes in the SN we observed a decrease in plasma glucose levels, decrease in lactate and glycogen in the brain, but significant increase in b-HB. This suggests a substantial shift in the use of energy substrates. We propose that ketone bodies locally produced in the brain could be relevant candidates to compensate neuronal needs for the death or prolonged astrocyte dysfunction. The research on multiple neuroprotective effects of ketogenic diet are in line with this conclusion.
Energy metabolism pathways
There were no changes in the expression of the glycolysis marker PKM2, at any time-point. In line with the observation, that astrocytes are mainly glycolytic (Dienel and Cruz 2006) , PKM2 is expressed exclusively in astrocytes (Zhang et al. 2014) and it regulates glycolytic flux in response to the local energy state (Almeida et al. 2004; Tech et al. 2017) . If the number of astrocytes was decreased after 7 days of FC infusion, it suggests that the lack of decrease in this protein means actually increased expression in the remaining, activated glial cells, in order to maintain the tissue energy metabolism.
After pyruvate formation catalyzed by PKM2, its flux into oxidative metabolism is controlled by the activity of the enzyme PDH (Zhang et al. 2014) . PDH links the glycolysis to the TCA cycle (Fig. 1) . It catalyzes the irreversible conversion of pyruvate to acetyl-CoA, which is the primary fuel for the TCA as well as for ketone body and fatty acid synthesis. Functioning of PDH is inhibited by phosphorylation by pyruvate dehydrogenase kinase (PDK). Its isoenzyme PDK2 shows higher expression in astrocytes than in neurons (Halim et al. 2010; Jha et al. 2016a) . The PDH/PDK system acts as a key regulator of mitochondrial activity and plays an important role in switching the metabolism from OxPhos to aerobic glycolysis due to the availability of pyruvate and acetyl-CoA (Jha et al. 2012) . We observed a significantly decreased expression of PDK2 in the SN after astrocyte degeneration. It might suggest that PDH activity was disinhibited and acetyl-CoA production enhanced, corresponding with increased b-HB production and CPT1a expression. In other studies, inhibition of PDK2 enzyme by dichloroacetic acid, dose-dependently lowered lactate production by astrocytes in culture (Halim et al. 2010) and reduced the elevated levels of lactate in the serum and CSF in patients with lactic acidosis (Jha et al. 2016a) . We also observed decreased lactate in the SN after FC. Furthermore, PDH in neurons operates at nearly maximal activity but in astrocytes it still has room for additional activation in different circumstances (Halim et al. 2010) . It corresponds with our results.
Fatty acid metabolism
In contrast to neurons, astrocytes are enriched in transcriptomes of genes encoding for enzymes involved in fatty acid oxidation and able to utilize it for bioenergetics requirements (Eraso-Pichot et al. 2018) . The CPT1 family of enzymes contains astrocytic CPT1a form localized in mitochondrial membrane and neuron specific CPT1c homologue in endoplasmic reticulum. CPT1a catalyzes the rate-limiting step for fatty acid oxidation via facilitation of their transport to the mitochondria. Importantly, enzymatic activity of neuronal CPT1c was not proven (Lee and Wolfgang 2012) , therefore, seems to play a role of a sensor of lipid metabolism in neurons (Casals et al. 2016) . Interestingly, CPT1c was reported to promote cell survival under metabolic stress in multiple cell types and stress conditions (Zaugg et al. 2011; Casals et al. 2016) . We observed increase in astrocytic CPT1a expression and neuronal CPT1c expression in the SN after astrocyte death. Together with the enhanced ketogenesis that requires acetyl-CoA from fatty acids for synthesis in astrocytes these data let us hypothesize enhanced fatty acid use in the tissue, probably as an adaptation to the disrupted astrocytic energy supply for neurons.
Aconitase
In the mammalian brain mitochondrial ACO is more abundant and sensitive than the cytosolic (Tretter and Adam-Vizi 2000; Li et al. 2001; Cantu et al. 2011) . mACO is the main TCA enzyme that reversibly converts citrate to isocitrate. Importantly, FC was documented to be predominantly taken up by glial cells through monocarboxylate transporter and to inhibit their aconitase, resulting in selective reduction of glial ATP production and overall metabolic stress (Paulsen et al. 1987; Hassel et al. 1992 Hassel et al. , 1994 Fonnum et al. 1997; Hirose et al. 2007; Zielke et al. 2007 Zielke et al. , 2009 . The previous studies proved that FC in vitro inhibited glial but not neuronal aconitase activity (Hassel et al. 1995; Zielke et al. 2009 ). Similarly to our data showing death of astrocytes but not neurons or microglia in the SN, the selectivity of FC towards glial cells was proven also after acute intranigral (Kuter et al. 2017) or intrastriatal injection (Paulsen et al. 1987; Hassel et al. 1992) .
Surprisingly, in the mitochondria samples after 7-day FC infusion we observed increased activity of mACO in the SN. This result was unexpected, since we did prove the selective death of astrocytes (Kuter et al. 2017) , therefore FC must have been working and inhibited mACO to induce the cell dysfunction and death. The decreased expression of GS, a selectively astrocytic enzyme downstream of mACO, further proves it. There are several possible explanations. It could be a compensatory increase in enzyme activity (no changes in the protein amount in the tissue, data not shown) due to the small but prolonged astrocyte mACO inhibition; hence the system had the time to adapt. The remaining, alive and activated astrocytes, surrounding the infusion site and dissected together with the tissue fragment (documented (Kuter et al. 2017) ), could be the source of this effect. Because we measured mACO activity in the whole SN tissue mitochondria, they are of both neuronal and glial origin. The other cell types, like neurons, could induce their mACO activity to enhance their energy production. Also, strong microglia activation (Kuter et al. 2017) and their enhanced metabolism for sure adds to the whole picture (see below).
The effect of microglia
On the one hand, we documented a significant decrease in the astrocyte number after prolonged FC infusion, but on the other, the remaining cells in the tissue surrounding the affected region were activated. Also, as we showed previously, microglial cells were strongly activated by stressed astrocytes (Kuter et al. 2017) . A shift in the cellular energy metabolism from OxPhos to aerobic glycolysis favors the microglia polarization towards a proinflammatory M1 phenotype (Jha et al. 2016a; Orihuela et al. 2016) . Augmented glucose uptake and metabolism was proven before to play a pivotal role in the activation of macrophages, involving PDK enzymes and enhanced pyruvate to acetyl-CoA conversion by PDH (Jha et al. 2016b ).
The main energy metabolism regulatory proteins -AMPK and PGC-1a A nuclear factor PGC-1a is one of the most important energy metabolism regulators, augmenting mitochondrial biogenesis (Casals et al. 2016) . It acts as a stress sensor, regulating metabolic adaptation, activated by nutrient deprivation. PGC1a influences mitochondrial respiration, reactive oxygen species (ROS) defense system, and fatty acid metabolism to maintain metabolic homeostasis and promote cell survival (Austin and St-Pierre 2012) . In this study, astrocyte death induced a strong increase in PGC-1a expression. It further strengthens the conclusion about local energetic stress caused by FC in the SN. Importantly, this result was highly significant, even though obtained from the whole tissue and mixed cell types with different energy metabolisms.
AMPK is an energy sensor, functioning as a master metabolic switch. It is activated by increases in AMP or ADP/ATP ratio under poor nutrient conditions (Zaugg et al. 2011) . AMPK activation by phosphorylation augments such metabolic pathways as fatty acid oxidation, glucose transport and mitochondrial biogenesis to maintain the cellular energy homeostasis. Its activation induces catabolism, use of alternative energy resources (Casals et al. 2016 ) and inhibition of ATP-consuming pathways (Mar ın-Aguilar et al. 2017). AMPK phosphorylates target proteins, such as PGC-1a (Zaugg et al. 2011; Casals et al. 2016 ) and glycogen-related proteins (Obel et al. 2012) . AMPK also regulates CPT1 protein family activity via phosphorylation of acetyl CoA carboxylase. Multiple factors in our study show changes, for which AMPK is known to be responsible. The lack of increased phosphorylation could be due to the differential energy metabolism in particular cell types in the tissue, as discussed above. All cells remaining in the tissue were activated, neurons devoid of astrocytic support, activated microglia and the remaining astrocytes but each of them has different energetic profile. Further studies dividing the observed effect between the cell types are needed.
Energy metabolism markers after partial lesion of dopaminergic neurons Injection of 6-OHDA into the MFB causes progressive degeneration of dopaminergic neurons in the SN and locomotor dysfunction. If the size of lesion is moderate animals adapt and dysfunction is reversed in time due to the compensatory processes. Lack of major decreases, in the studied here parameters, despite the loss of 40-50% of dopaminergic neurons in the tissue, could indicate that remaining neurons proportionally increased their functioning to compensate.
Furthermore, our previous studies in this model showed that death of 30% of astrocytes does not enhance the degeneration of neurons but accelerates it (Kuter et al. 2018 ) and the current results on energy metabolism markers are in line with it. These results correspond to the presymptomatic phase of PD, with minimal changes in the brain energetics, and further indicate that astrocytes could be responsible for the primary cause of the disease and progressive neuronal death.
Importantly, the prolonged destruction of astrocytes blocked the compensatory process of locomotor behavior improvement with time. The changes in metabolic markers we observed implicate that the support required for the compensation was not fulfilled for surviving neurons to be effective in maintaining the normal dopaminergic system functioning, when astrocytes were defective. The changes observed after combined assault on astrocytes and neurons in the SN showed enhanced effects. After 7 days the loss of both, glycogen in the SN and glucose in blood resulted in the enhanced decrease in the SN lactate levels. Also, plasma lactate levels were decreased suggesting an additive effect. After 4 weeks, despite the increased lactate level after FC alone, it did not increase after combined assault in the SN and in the STR was even lower. The increased glycogen expression and mACO activity in the STR could reflect the further compensatory effort of the dopaminergic system terminals to maintain the energy requirements.
Conclusions
This study shows animal model of astrocyte destruction by chronic FC infusion into the SN that induced a local energy deprivation. Although we did not study functional parameters of energy metabolism analyzed markers suggest a concomitant shift in the content of energy substrates, via increased glycogenolysis and glycolysis markers, ketone bodies amount and fatty acid transport protein expression in the remaining cells. The data presented here further prove selectivity of the model in vivo. Additionally, we found that increased expression of CPT1c in neurons plays a role in the adaptation to astrocyte death. Also, PGC-1a and AMPK as energy sensors seem to act differently in the various cell types. The metabolic marker changes observed in this study implicate that the support required for compensation of dopaminergic neuron death was not enough, when astrocytes were defective. Therefore, astrocytes are essential for neuronal compensatory potential in early PD stages and could be used in future to develop diagnostics and protective therapeutic approach.
